Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Patent
1998-09-29
2000-03-07
Bernhardt, Emily
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
544366, A61K 31495, C07D40306
Patent
active
060340851
ABSTRACT:
The crystalline, stable methanesulfonate salt of nefazodone showed significantly higher intrinsic dissolution in water and THAM buffer (pH 7.5) compared to other salts of nefazodone. The faster dissolution rate of this salt at neutral pH suggests better dissolution and absorption in the intestine, allowing controlled release of nefazodone for oral formulations.
REFERENCES:
patent: 3381009 (1968-04-01), Palazzo et al.
patent: 4338317 (1982-07-01), Temple et al.
patent: 4487773 (1984-12-01), Temple et al.
patent: 4910196 (1990-03-01), Terni et al.
patent: 5188836 (1993-02-01), Muhammad et al.
Agharkar, et al., "Enhancement of Solubility of Drug Salts by Hydrophilic Counterions: Properties of Organic Salts of an Antimalarial Drug," Journal of Pharmaceutical Sciences, vol. 65, No. 5, May 1976, pp. 747-749.
Joshi Hemant N.
Patel Jatin M.
Wilson Terry D.
Bernhardt Emily
Bristol-Myers Squibb Co.
Ryan Richard P.
LandOfFree
Salt form of nefazodone for use in extended release formulations does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Salt form of nefazodone for use in extended release formulations, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Salt form of nefazodone for use in extended release formulations will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-363348